Quoin Pharmaceuticals Ltd. (QNRX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth No data; EPS growth No data.
- 2026-Q1: Total return Lose; Revenue growth No data; EPS growth No data.
- 2025-Q4: Total return Win; Revenue growth No data; EPS growth No data.
- 2025-Q3: Total return Lose; Revenue growth No data; EPS growth No data.
10/39
1.3 / 5 stars
All 39 Win/Lose results and 81 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 1 wins, 3 losses, 8 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/1 |
LoseQNRX / S&P -26.67% / 15.20% |
No dataQNRX / S&P / 15.00% |
No dataQNRX / S&P / 50.40% |
| 2026-Q10/1 |
LoseQNRX / S&P -54.26% / -4.33% |
No dataQNRX / S&P / 11.30% |
No dataQNRX / S&P / 27.70% |
| 2025-Q41/1 |
WinQNRX / S&P 100.70% / 2.65% |
No dataQNRX / S&P / 9.00% |
No dataQNRX / S&P / 13.40% |
| 2025-Q30/1 |
LoseQNRX / S&P -22.10% / 8.12% |
No dataQNRX / S&P / 4.61% |
No dataQNRX / S&P / 13.45% |
| 2025-Q21/1 |
WinQNRX / S&P 17.73% / 10.94% |
No dataQNRX / S&P / 4.83% |
No dataQNRX / S&P / 10.63% |
| 2025-Q10/1 |
LoseQNRX / S&P -65.59% / -4.27% |
No dataQNRX / S&P / 4.98% |
No dataQNRX / S&P / 10.57% |
| 2024-Q41/1 |
WinQNRX / S&P 32.05% / 2.41% |
No dataQNRX / S&P / 5.25% |
No dataQNRX / S&P / 6.15% |
| 2024-Q30/1 |
LoseQNRX / S&P -15.00% / 5.89% |
No dataQNRX / S&P / 5.89% |
No dataQNRX / S&P / 6.11% |
| 2024-Q20/1 |
LoseQNRX / S&P -38.95% / 4.28% |
No dataQNRX / S&P / 5.38% |
No dataQNRX / S&P / 5.12% |
| 2024-Q10/1 |
LoseQNRX / S&P -80.63% / 10.56% |
No dataQNRX / S&P / 5.71% |
No dataQNRX / S&P / 5.59% |
| 2023-Q41/1 |
WinQNRX / S&P 18.19% / 11.69% |
No dataQNRX / S&P / 6.81% |
No dataQNRX / S&P / 7.78% |
| 2023-Q30/1 |
LoseQNRX / S&P -30.83% / -3.27% |
No dataQNRX / S&P / 7.52% |
No dataQNRX / S&P / -5.03% |
| 2023-Q20/1 |
LoseQNRX / S&P 5.04% / 8.74% |
No dataQNRX / S&P / 9.50% |
No dataQNRX / S&P / -8.57% |
| 2023-Q10/1 |
LoseQNRX / S&P -66.48% / 7.50% |
No dataQNRX / S&P / 10.77% |
No dataQNRX / S&P / -15.69% |
| 2022-Q40/1 |
LoseQNRX / S&P -36.32% / 7.56% |
No dataQNRX / S&P / 11.88% |
No dataQNRX / S&P / -17.99% |
| 2022-Q30/1 |
LoseQNRX / S&P -60.36% / -4.88% |
No dataQNRX / S&P / 13.47% |
No dataQNRX / S&P / -1.41% |
| 2022-Q20/1 |
LoseQNRX / S&P -66.17% / -16.10% |
No dataQNRX / S&P / 13.71% |
No dataQNRX / S&P / 11.04% |
| 2022-Q10/1 |
LoseQNRX / S&P -26.92% / -4.60% |
No dataQNRX / S&P / 15.97% |
No dataQNRX / S&P / 42.23% |
| 2021-Q40/1 |
LoseQNRX / S&P -90.14% / 11.03% |
No dataQNRX / S&P / 15.00% |
No dataQNRX / S&P / 96.40% |
| 2021-Q31/1 |
WinQNRX / S&P 23.07% / 0.58% |
No dataQNRX / S&P / 10.77% |
No dataQNRX / S&P / 69.42% |
| 2021-Q21/1 |
WinQNRX / S&P 19.43% / 8.55% |
No dataQNRX / S&P / 6.58% |
No dataQNRX / S&P / 51.81% |
| 2021-Q11/1 |
WinQNRX / S&P 45.37% / 6.17% |
No dataQNRX / S&P / -1.06% |
No dataQNRX / S&P / 7.39% |
| 2020-Q40/1 |
LoseQNRX / S&P 2.86% / 12.15% |
No dataQNRX / S&P / -3.72% |
No dataQNRX / S&P / -33.42% |
| 2020-Q30/1 |
LoseQNRX / S&P -33.33% / 8.93% |
No dataQNRX / S&P / -2.04% |
No dataQNRX / S&P / -27.10% |
| 2020-Q21/1 |
WinQNRX / S&P 114.29% / 20.54% |
No dataQNRX / S&P / -0.46% |
No dataQNRX / S&P / -27.11% |
| 2020-Q10/1 |
LoseQNRX / S&P -33.78% / -19.60% |
No dataQNRX / S&P / 3.47% |
No dataQNRX / S&P / -14.75% |
| 2019-Q40/1 |
LoseQNRX / S&P -9.02% / 9.07% |
No dataQNRX / S&P / 5.36% |
No dataQNRX / S&P / 2.99% |
| 2019-Q30/1 |
LoseQNRX / S&P -4.31% / 1.70% |
No dataQNRX / S&P / 5.02% |
No dataQNRX / S&P / 0.21% |
| 2019-Q20/1 |
LoseQNRX / S&P -49.55% / 4.30% |
No dataQNRX / S&P / 6.64% |
No dataQNRX / S&P / 8.65% |
| 2019-Q10/1 |
LoseQNRX / S&P -51.86% / 13.65% |
No dataQNRX / S&P / 8.12% |
No dataQNRX / S&P / 14.29% |
| 2018-Q40/1 |
LoseQNRX / S&P -55.88% / -13.52% |
No dataQNRX / S&P / 9.05% |
No dataQNRX / S&P / 18.23% |
| 2018-Q30/1 |
LoseQNRX / S&P -33.43% / 7.71% |
No dataQNRX / S&P / 10.21% |
No dataQNRX / S&P / 19.06% |
| 2018-Q21/1 |
WinQNRX / S&P 12.07% / 3.43% |
No dataQNRX / S&P / 9.03% |
No dataQNRX / S&P / 14.46% |
| 2018-Q10/1 |
LoseQNRX / S&P -8.86% / -0.76% |
No dataQNRX / S&P / 7.68% |
No dataQNRX / S&P / 12.46% |
| 2017-Q40/1 |
LoseQNRX / S&P -11.95% / 6.64% |
No dataQNRX / S&P / 7.03% |
No dataQNRX / S&P / 13.82% |
| 2017-Q30/1 |
LoseQNRX / S&P -1.36% / 4.48% |
No dataQNRX / S&P / 5.68% |
No dataQNRX / S&P / 17.57% |
| 2017-Q20/1 |
LoseQNRX / S&P -6.28% / 3.09% |
No dataQNRX / S&P / 4.83% |
No dataQNRX / S&P / 17.74% |
| 2017-Q11/1 |
WinQNRX / S&P 178.32% / 6.07% |
No dataQNRX / S&P / 3.67% |
No dataQNRX / S&P / 13.32% |
| 2016-Q40/1 |
LoseQNRX / S&P -32.83% / 3.82% |
No dataQNRX / S&P / 2.09% |
No dataQNRX / S&P / 7.05% |
| 2016-Q30/0 |
No dataQNRX / S&P / 3.85% |
No dataQNRX / S&P / 0.20% |
No dataQNRX / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | QNRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -30.10% | 20.78% |
| Annualized return | -30.10% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | QNRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 83.14% |
| Annualized return | -86.33% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | QNRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -68.03% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |